Skip to main content
Explore URMC

URMC Logo

menu

Yi Zhang, Ph.D., M.S., M.B.A.

Contact Information

Phone Numbers

Office: (585) 275-1950

Fax: (585) 756-4468

Research Labs

Biography

Dr. Zhang has studied the Wnt signaling pathway, first as a graduate student and then as a postdoctoral fellow at Yale. He is currently working on mechanisms of hematopoietic stem cells (HSC) and leukemia initiating cells (LIC) regulations using a combination of mouse genetics and chemical genetics approaches.

Research

Dr. Zhang's graduate work revealed a role for the Wnt regulator Axin in the regulation of Jun N-terminal kinase. As a postdoc, he discovered a connection between the anti-angiogenesis drug fumagillin and the Wnt signaling pathway, which both provided strong evidence for the role of the Wnt pathway in angiogenesis, as well as explained the role of the fumagillin target, MetAP2, in cellular growth control.

Credentials

Faculty Appointments

Education

1990
BS | Fudan University
Biophysics and Physiology

2001
PhD | National University of Singapore (rank Top 3 in Asia), IMCB, A-STAR and NUS
Molecular and Cell Biology

2004
Post-doc Training (2002-2004) | Yale University
Chemical Genetics Chemical Genomics (advisor: Craig M Crews, AAAS Fellow, Director Yale Center for Molecular Discovery, Lab of Invention of FDA-approved drug Carfilzomib/KyprolisTM), Yale University

2007
Promoted to Research Faculty (2004 -2007) after Post-Doc Training | Yale University
Chemical Genetics Chemical Genomics (advisor: Craig M Crews, AAAS Fellow, Director Yale Center for Molecular Discovery, Lab of Invention of FDA-approved drug Carfilzomib/KyprolisTM), Yale University

2012
MS | Simon Business School, University of Rochester
Medical Management

2014
MBA Class of 2014 | Simon Business School, University of Rochester
Business Administration

Awards

2014 - Present
New York State Stem Cell Sciences funding
Sponsor: New York State Department of Health

2011
Empire State Stem Cell Board IDEA Award
Sponsor: New York State

2008
James P. Wilmot Cancer Center Symposium 1st place award
Sponsor: University of Rochester Medical Center

2006
Advanced Training in Science Teaching
Sponsor: Yale Graduate Teaching Center

2003
Life Science Research Foundation Finalist
Sponsor: Princeton University

2003
Helen Hay Whitney Foundation finalist

VIEW ALL expand_more

Publications

Journal Articles

3/2017
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. "The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia." Nature medicine.. 2017 Mar 0; 23(3):301-313. Epub 2017 Feb 13.

6/24/2016
Wilson M, Tsakraklides V, Tran M, Xiao YY, Zhang Y, Perkins AS. "EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements." The Journal of biological chemistry.. 2016 Jun 24; 291(26):13591-607. Epub 2016 Apr 21.

3/2014
Juneja SC, Vonica A, Zeiss C, Lezon-Geyda K, Yatsula B, Sell DR, Monnier VM, Lin S, Ardito T, Eyre D, Reynolds D, Yao Z, Awad HA, Yu H, Wilson M, Honnons S, Boyce BF, Xing L, Zhang Y, Perkins AS. "Deletion of Mecom in mouse results in early-onset spinal deformity and osteopenia." Bone.. 2014 Mar 0; 60:148-61. Epub 2013 Dec 04.

VIEW ALL PUBLICATIONS